Apple Tree Partners II

Red Queen Therapeutics is a biotechnology company engaged in the research, development, and production of innovative products across medicine and agriculture. The company focuses on creating biotechnology drugs that aim to provide rapid responses to current and emerging pathogens that pose risks to human health. Utilizing a unique plug-and-play antiviral platform based on stapled peptide decoys, Red Queen Therapeutics is equipped to swiftly address both pandemic and non-pandemic viruses, as well as other viral infections that often go untreated. In addition to its medical applications, the company's work extends to agricultural sectors, where it contributes to crop production and non-food uses of crops, ensuring a wide range of commercial applications for its biotechnological advancements.

Deep Apple Therapeutics is a biotechnology research company that specializes in the discovery of new small-molecule therapeutics. The company leverages advanced computer-aided drug design technologies, integrating molecular docking and structural biology to enhance the drug discovery process. By combining these capabilities, Deep Apple Therapeutics aims to streamline and accelerate the development of new pharmaceuticals, providing clients with innovative solutions in the field of drug discovery.

Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time. With active discovery and preclinical programs in ophthalmology, neurological and neuromuscular disorders, and other rare diseases, Ascidian is opening new therapeutic possibilities for patients in need of breakthroughs.

Aulos Bioscience is a biotechnology company focused on transforming cancer treatment through innovative immuno-oncology therapeutics. The company aims to enhance patient care by developing targeted antibodies that direct the immune system to effectively eliminate tumor cells. Their approach emphasizes precision in targeting solid tumors, allowing healthcare providers to deliver more effective therapies. By concentrating on this niche within cancer treatment, Aulos Bioscience seeks to provide advanced solutions that can significantly improve patient outcomes.

Initial Therapeutics focuses on developing small-molecule medicines aimed at preventing the synthesis of pathogenic proteins. Unlike traditional methods that target proteins after they have formed, the company’s innovative approach addresses these proteins at an earlier stage, which is particularly beneficial for challenging drug targets. By doing so, Initial Therapeutics seeks to meet significant unmet medical needs in healthcare, providing new therapeutic options for conditions that are difficult to treat.

Aethon Therapeutics is focused on advancing cancer treatment through a novel approach that combines immunotherapy with targeted therapies. The company develops unique anti-drug-peptide conjugate/MHC antibodies that work in conjunction with targeted covalent inhibitors aimed at oncogenic mutations such as RAS and EGFR. This innovative platform is designed to create neoantigens by design, enhancing the immune system's ability to selectively attack and eliminate residual cancer cells, including those that are drug-resistant. By integrating these technologies, Aethon Therapeutics aims to transform cancer treatments into potential cures, offering new hope for patients facing challenging forms of the disease.

Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time. With active discovery and preclinical programs in ophthalmology, neurological and neuromuscular disorders, and other rare diseases, Ascidian is opening new therapeutic possibilities for patients in need of breakthroughs.

Galvanize Therapeutics is a medical technology company specializing in energy-based devices aimed at improving biological processes for therapeutic applications. Founded in 2022 by Apple Tree Partners, the company focuses on developing innovative solutions to treat various medical conditions, including chronic bronchitis, cardiac arrhythmias, and solid tumors. Its platform employs short-duration, high-voltage electrical pulses to create electric fields that destabilize cells through multiple biochemical mechanisms. This technology enhances the ability of medical professionals to provide effective healthcare services, positioning Galvanize Therapeutics as a potential leader in delivering cutting-edge medical innovations.

Adendra Therapeutics is an emerging biotechnology company focused on harnessing insights into dendritic cell biology to create innovative small molecules and biologic medicines. The company specializes in the discovery and development of therapeutics aimed at treating various cancers and autoimmune diseases. By leveraging the unique properties of dendritic cells, particularly their ability to cross-present antigens, Adendra seeks to contribute to more effective cancer treatments and improve outcomes in the healthcare sector.

Marengo Therapeutics is focused on developing immune activation therapeutics aimed at treating cancer. The company's innovative antibodies are designed to induce targeted and lasting anti-tumor responses in solid tumor models. By promoting protective tumor immunity and triggering cytokine release, Marengo Therapeutics enhances the expansion of antigen-specific memory T cells. This approach aims to empower patients in their battle against challenging and life-threatening diseases, ultimately improving treatment outcomes.

Intergalactic Therapeutics is innovating the field of gene therapy through its unique non-viral platform, which utilizes synthetic and episomal C3DNA (covalently closed and circular DNA) molecules. The company has developed a customized approach for targeted therapeutic delivery, highlighted by its advanced COMET® pulsed electric field system. Additionally, Intergalactic Therapeutics employs a proprietary cell-free manufacturing process that aims to enhance the safety and accessibility of gene therapies for patients. The company's research and development efforts span various medical areas, including ophthalmology, oncology, respiratory diseases, and potential expansion into central nervous system, renal, and musculoskeletal conditions. Through these initiatives, Intergalactic Therapeutics is committed to advancing genetic medicine and addressing the challenges associated with traditional viral-based therapies.

Replicate Bioscience is focused on developing innovative oncology treatments aimed at preventing and reversing drug resistance in cancer therapies. Utilizing a self-replicating RNA platform known as SynRGY, the company seeks to create novel treatments that enhance the effectiveness of various immuno-oncology regimens. By leveraging synthetic biology, Replicate Bioscience aims to provide healthcare professionals with advanced therapeutic options that not only detect and eliminate cancerous cells but also improve patient outcomes in cancer treatment.

Galaxy Medical is a privately held medical device company focused on developing advanced technologies for the treatment of cardiac arrhythmia. The company specializes in a device that employs pulsed electric field technology, utilizing high voltage and high-frequency bursts of electro-surgical energy to ablate tissue. This innovative approach allows electrophysiologists to conduct safe and effective ablation procedures, ultimately enhancing patient outcomes in cardiac care.

Replicate Bioscience is focused on developing innovative oncology treatments aimed at preventing and reversing drug resistance in cancer therapies. Utilizing a self-replicating RNA platform known as SynRGY, the company seeks to create novel treatments that enhance the effectiveness of various immuno-oncology regimens. By leveraging synthetic biology, Replicate Bioscience aims to provide healthcare professionals with advanced therapeutic options that not only detect and eliminate cancerous cells but also improve patient outcomes in cancer treatment.

Aulos Bioscience is a biotechnology company focused on transforming cancer treatment through innovative immuno-oncology therapeutics. The company aims to enhance patient care by developing targeted antibodies that direct the immune system to effectively eliminate tumor cells. Their approach emphasizes precision in targeting solid tumors, allowing healthcare providers to deliver more effective therapies. By concentrating on this niche within cancer treatment, Aulos Bioscience seeks to provide advanced solutions that can significantly improve patient outcomes.

Ascidian Therapeutics is redefining the treatment of disease by rewriting RNA. By editing exons at the RNA level, Ascidian therapies enable precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time. With active discovery and preclinical programs in ophthalmology, neurological and neuromuscular disorders, and other rare diseases, Ascidian is opening new therapeutic possibilities for patients in need of breakthroughs.

Intergalactic Therapeutics is innovating the field of gene therapy through its unique non-viral platform, which utilizes synthetic and episomal C3DNA (covalently closed and circular DNA) molecules. The company has developed a customized approach for targeted therapeutic delivery, highlighted by its advanced COMET® pulsed electric field system. Additionally, Intergalactic Therapeutics employs a proprietary cell-free manufacturing process that aims to enhance the safety and accessibility of gene therapies for patients. The company's research and development efforts span various medical areas, including ophthalmology, oncology, respiratory diseases, and potential expansion into central nervous system, renal, and musculoskeletal conditions. Through these initiatives, Intergalactic Therapeutics is committed to advancing genetic medicine and addressing the challenges associated with traditional viral-based therapies.

Marengo Therapeutics is focused on developing immune activation therapeutics aimed at treating cancer. The company's innovative antibodies are designed to induce targeted and lasting anti-tumor responses in solid tumor models. By promoting protective tumor immunity and triggering cytokine release, Marengo Therapeutics enhances the expansion of antigen-specific memory T cells. This approach aims to empower patients in their battle against challenging and life-threatening diseases, ultimately improving treatment outcomes.

Nereid Therapeutics Inc. is engaged in the discovery of small molecules aimed at modulating protein interactions associated with various disease states. Based in Cambridge, Massachusetts, the company employs proprietary technologies to generate, visualize, and measure liquid-liquid phase separation and the resultant biomolecular condensates. Through its innovative approach, Nereid Therapeutics seeks to develop new treatments for diseases by targeting the underlying mechanisms of protein interactions.

Galaxy Medical is a privately held medical device company focused on developing advanced technologies for the treatment of cardiac arrhythmia. The company specializes in a device that employs pulsed electric field technology, utilizing high voltage and high-frequency bursts of electro-surgical energy to ablate tissue. This innovative approach allows electrophysiologists to conduct safe and effective ablation procedures, ultimately enhancing patient outcomes in cardiac care.

Initial Therapeutics focuses on developing small-molecule medicines aimed at preventing the synthesis of pathogenic proteins. Unlike traditional methods that target proteins after they have formed, the company’s innovative approach addresses these proteins at an earlier stage, which is particularly beneficial for challenging drug targets. By doing so, Initial Therapeutics seeks to meet significant unmet medical needs in healthcare, providing new therapeutic options for conditions that are difficult to treat.

Nine Square Therapeutics focuses on developing small-molecule therapeutics aimed at treating degenerative movement disorders such as Parkinson's disease and amyotrophic lateral sclerosis (ALS), as well as non-degenerative conditions like essential tremor and dyskinesias. Founded in 2020 and based in New York, the company employs a combination of computational chemistry, biophysics, and computational biology, utilizing machine-learning-enabled cell profiling platforms for target identification, chemical optimization, and patient stratification. This innovative approach allows for a more efficient and effective strategy in addressing the challenges posed by these complex medical conditions.

Gala Therapeutics is a privately-held medical device company based in Menlo Park, California, that focuses on developing disease-modifying therapies aimed at improving survival and quality of life for patients with lung cancer, chronic obstructive pulmonary disease (COPD), asthma, and other pulmonary conditions. Established in 2015, the company offers innovative solutions that cater to the needs of interventional pulmonologists and thoracic surgeons. Its main product consists of a single-use catheter and an electrosurgical generator designed to deliver non-thermal energy to the airways, effectively reducing mucus-producing cells in patients. This technology enables healthcare providers to enhance treatment outcomes for their patients, addressing critical challenges in pulmonary disease management.

Chinook Therapeutics, Inc. is a clinical-stage biotechnology company based in Seattle, Washington, that specializes in the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead program is atrasentan, an investigational endothelin receptor antagonist currently prepared for Phase III trials targeting IgA nephropathy and other primary glomerular diseases. In addition to atrasentan, Chinook is developing BION-1301, an investigational anti-APRIL monoclonal antibody evaluated in a Phase Ib trial for IgA nephropathy, and CHK-336, a preclinical candidate aimed at treating an undisclosed ultra-orphan kidney disease. Chinook Therapeutics is also engaged in research programs addressing other rare and severe chronic kidney conditions, including polycystic kidney disease.

Bellus Health is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for rare diseases, with a particular focus on conditions affecting the kidneys. Its lead drug candidate, KIACTA™, is designed for the treatment of AA amyloidosis, a rare condition that can result in severe renal dysfunction. Following the successful completion of a Phase 3 study, the company is collaborating with Auven Therapeutics to advance KIACTA™, which is also being explored for treating sarcoidosis, an inflammatory disease affecting the lungs. Additionally, Bellus Health is developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome, a serious condition linked to Shiga toxin-producing E. coli, which poses significant health risks, especially for children. The company's research pipeline also includes efforts to address AL amyloidosis, another rare disease characterized by the accumulation of amyloid proteins in the body. Bellus Health aims to meet the high unmet medical needs of patients suffering from these conditions through its focused therapeutic developments.

Stoke Therapeutics, Inc. is an early-stage biopharmaceutical company headquartered in Bedford, Massachusetts, focused on developing novel antisense oligonucleotide medicines to address the underlying causes of severe genetic diseases. The company employs its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) technology to enhance gene expression by targeting RNA splicing, thereby selectively restoring protein levels. Its lead product candidate, STK-001, is currently in clinical testing for the treatment of Dravet syndrome, a serious and progressive genetic epilepsy. Established in 2014, Stoke Therapeutics also collaborates with Invitae Corporation to provide genetic testing services, further supporting its mission to advance gene-targeted therapies for patients with severe genetic conditions.

Akero Therapeutics is a clinical-stage biotechnology company based in South San Francisco, California, that specializes in developing treatments for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). Founded in 2017 and formerly known as Pippin Pharmaceuticals, the company is dedicated to addressing the significant unmet medical needs associated with NASH, a condition characterized by liver inflammation and damage, which can lead to severe complications such as fibrosis and liver failure. Akero's lead product candidate, AKR-001, is a long-acting Fc fusion modified FGF21 protein designed to restore metabolic balance by targeting both liver and adipose tissues, thereby reducing liver fat and suppressing inflammation and fibrosis. This innovative approach builds upon two decades of research into FGF21 biology, positioning Akero as a frontrunner in the quest for effective NASH therapies.

Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, specializing in the development of precision cardiovascular therapies. Founded in 2014, the company focuses on researching and commercializing innovative treatments for cardio-renal diseases. Corvidia is particularly engaged in developing therapies for chronic kidney disease associated with atherosclerotic cardiovascular disease, inflammation, and high triglyceride-induced acute pancreatitis. As of July 2020, Corvidia operates as a subsidiary of Novo Nordisk A/S, leveraging its expertise to advance its clinical-stage programs aimed at addressing specific biological pathways in patients with unique sensitivities.

Braeburn Inc. is a pharmaceutical company focused on developing and commercializing treatments for serious central nervous system disorders, with a primary emphasis on opioid addiction. Founded in 2012 and headquartered in Plymouth Meeting, Pennsylvania, Braeburn aims to provide innovative solutions for individuals affected by opioid use disorder (OUD). The company's lead product candidate, BRIXADI, is an extended-release injectable formulation of buprenorphine designed for the treatment of moderate to severe OUD. Braeburn is committed to advancing next-generation therapies that offer individualized dosing regimens and delivery options, striving to improve care for patients and address the growing challenges associated with addiction.

Stoke Therapeutics, Inc. is an early-stage biopharmaceutical company headquartered in Bedford, Massachusetts, focused on developing novel antisense oligonucleotide medicines to address the underlying causes of severe genetic diseases. The company employs its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) technology to enhance gene expression by targeting RNA splicing, thereby selectively restoring protein levels. Its lead product candidate, STK-001, is currently in clinical testing for the treatment of Dravet syndrome, a serious and progressive genetic epilepsy. Established in 2014, Stoke Therapeutics also collaborates with Invitae Corporation to provide genetic testing services, further supporting its mission to advance gene-targeted therapies for patients with severe genetic conditions.

Elstar Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2015. The company focuses on developing innovative immunotherapies aimed at treating a range of diseases, particularly in the fields of oncology and autoimmunity. Elstar Therapeutics is dedicated to advancing precision cancer immunotherapy by creating antibody-based, multi-functional therapeutics that enhance treatment efficacy.

Syntimmune, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on developing innovative drug candidates for a variety of autoimmune diseases. Founded in 2013 by Laurence and Richard Blumberg, Syntimmune leverages its expertise in the biology of the neonatal Fc receptor (FcRn) to advance novel therapies targeting IgG-mediated autoimmune conditions. The company's platform centers on creating humanized monoclonal antibodies that inhibit the interaction between FcRn and Immunoglobulin G (IgG), aiming to provide transformative treatments for patients suffering from rare IgG-mediated diseases. As of November 2018, Syntimmune operates as a subsidiary of Alexion Pharmaceuticals, Inc.

Syntimmune, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on developing innovative drug candidates for a variety of autoimmune diseases. Founded in 2013 by Laurence and Richard Blumberg, Syntimmune leverages its expertise in the biology of the neonatal Fc receptor (FcRn) to advance novel therapies targeting IgG-mediated autoimmune conditions. The company's platform centers on creating humanized monoclonal antibodies that inhibit the interaction between FcRn and Immunoglobulin G (IgG), aiming to provide transformative treatments for patients suffering from rare IgG-mediated diseases. As of November 2018, Syntimmune operates as a subsidiary of Alexion Pharmaceuticals, Inc.

ROX Medical, Inc. is a medical device company based in San Clemente, California, specializing in interventional vascular therapy devices aimed at treating uncontrolled hypertension and chronic obstructive pulmonary disease (COPD). The company develops the ROX Coupler, which is designed to lower blood pressure in patients with treatment-resistant hypertension by reducing peripheral vascular resistance and enhancing vascular compliance. Additionally, the device aims to improve oxygen delivery to tissues in COPD patients, helping to alleviate symptoms and enhance exercise tolerance. Founded in 2003, ROX Medical focuses on innovative solutions that enhance patient well-being through advanced medical technology.

VytronUS, Inc. specializes in the manufacture and marketing of cardiac medical devices aimed at treating cardiac arrhythmias. Founded in 2006 and located in Sunnyvale, California, the company focuses on leveraging ultrasound energy to enhance the imaging and therapeutic capabilities of its devices. These innovative products allow for precise non-contact energy delivery and facilitate the production of high-resolution maps of cardiac anatomy. By providing physicians with tools that enable visualization, precision, flexibility, and automation, VytronUS aims to improve the treatment of complex arrhythmias.

Syntimmune, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on developing innovative drug candidates for a variety of autoimmune diseases. Founded in 2013 by Laurence and Richard Blumberg, Syntimmune leverages its expertise in the biology of the neonatal Fc receptor (FcRn) to advance novel therapies targeting IgG-mediated autoimmune conditions. The company's platform centers on creating humanized monoclonal antibodies that inhibit the interaction between FcRn and Immunoglobulin G (IgG), aiming to provide transformative treatments for patients suffering from rare IgG-mediated diseases. As of November 2018, Syntimmune operates as a subsidiary of Alexion Pharmaceuticals, Inc.

Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, specializing in the development of precision cardiovascular therapies. Founded in 2014, the company focuses on researching and commercializing innovative treatments for cardio-renal diseases. Corvidia is particularly engaged in developing therapies for chronic kidney disease associated with atherosclerotic cardiovascular disease, inflammation, and high triglyceride-induced acute pancreatitis. As of July 2020, Corvidia operates as a subsidiary of Novo Nordisk A/S, leveraging its expertise to advance its clinical-stage programs aimed at addressing specific biological pathways in patients with unique sensitivities.

QualDerm Partners specializes in offering strategic leadership and practice management services to dermatologists and skin care professionals throughout the southeastern United States. By focusing on a practice-centric philosophy, QualDerm enables healthcare providers to prioritize patient care while minimizing administrative burdens. The company provides essential management support, capital, and guidance, facilitating sustainable growth and profitability for dermatological practices. This approach allows physicians to concentrate on delivering quality care while efficiently managing the operational and administrative aspects of their practices.

Cure Forward is a healthcare company focused on genomic medicine, particularly in the oncology sector. Established in 2014 and based in Boston, Massachusetts, it operates an online portal that allows cancer patients and their physicians to access and share genomic testing data. This platform facilitates interaction between users and helps them explore additional treatment options, including participation in relevant clinical trials. By providing a web-based community, Cure Forward enables patients and their families to go beyond standard medical lab reports and engage more fully with the possibilities offered by genomic medicine.

Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, dedicated to developing innovative therapeutics, particularly stabilized cell-permeating alpha-helical peptides, for oncology and other therapeutic areas. The company’s lead product candidate, ALRN-6924, is designed to treat advanced solid tumors and is currently undergoing various clinical trials, including Phase 2a studies for peripheral T-cell lymphoma and advanced solid tumors, as well as Phase 1 trials for acute myeloid leukemia and myelodysplastic syndromes. Aileron Therapeutics also explores next-generation wild type p53 reactivators and has established collaborations with notable institutions such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer to evaluate the effectiveness of ALRN-6924 in combination with other treatments. Founded in 2001 and originally known as Renegade Therapeutics, the company aims to address critical cell functions through its novel approach to modulating protein-protein interactions.

VytronUS, Inc. specializes in the manufacture and marketing of cardiac medical devices aimed at treating cardiac arrhythmias. Founded in 2006 and located in Sunnyvale, California, the company focuses on leveraging ultrasound energy to enhance the imaging and therapeutic capabilities of its devices. These innovative products allow for precise non-contact energy delivery and facilitate the production of high-resolution maps of cardiac anatomy. By providing physicians with tools that enable visualization, precision, flexibility, and automation, VytronUS aims to improve the treatment of complex arrhythmias.

Syntimmune, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on developing innovative drug candidates for a variety of autoimmune diseases. Founded in 2013 by Laurence and Richard Blumberg, Syntimmune leverages its expertise in the biology of the neonatal Fc receptor (FcRn) to advance novel therapies targeting IgG-mediated autoimmune conditions. The company's platform centers on creating humanized monoclonal antibodies that inhibit the interaction between FcRn and Immunoglobulin G (IgG), aiming to provide transformative treatments for patients suffering from rare IgG-mediated diseases. As of November 2018, Syntimmune operates as a subsidiary of Alexion Pharmaceuticals, Inc.

Dermira, Inc. is a biopharmaceutical company based in Menlo Park, California, that focuses on developing and commercializing therapies for dermatologic conditions in the United States. The company offers QBREXZA, a once-daily topical treatment for primary axillary hyperhidrosis in patients aged nine years and older. Additionally, Dermira is advancing several product candidates, including lebrikizumab, a monoclonal antibody currently in Phase IIb trials for moderate-to-severe atopic dermatitis, and glycopyrronium tosylate, which is in Phase III trials for hyperhidrosis. Dermira also has collaborations with other companies for the development and commercialization of its products, such as a partnership with UCB Pharma for Cimzia, aimed at treating chronic plaque psoriasis. Founded in 2010, Dermira aims to provide innovative solutions for dermatologists and their patients.

Cerecor Inc. is a biopharmaceutical company dedicated to the development and commercialization of treatments for rare pediatric and orphan diseases. Founded in 2011 and headquartered in Rockville, Maryland, the company is advancing a clinical-stage pipeline that includes therapies for inherited metabolic disorders, such as CERC-801, CERC-802, and CERC-803, which are focused on congenital disorders of glycosylation. Additionally, Cerecor is developing CERC-006, an oral mTOR inhibitor aimed at treating complex lymphatic malformations, and two monoclonal antibodies: CERC-002, targeting the cytokine LIGHT for severe pediatric-onset Crohn's disease, and CERC-007, targeting IL-18 for autoimmune inflammatory diseases like adult onset Still's disease and multiple myeloma. Several of these therapies have received Orphan Drug Designation and Rare Pediatric Disease Designation, qualifying them for expedited review upon FDA approval. Cerecor also offers Millipred, an oral prednisolone for various inflammatory conditions.

Tendyne Holdings Inc. is a clinical-stage medical device company based in Roseville, Minnesota, focused on developing innovative, minimally invasive therapies for mitral regurgitation, a condition affecting numerous individuals globally each year. Founded in 2010, the company specializes in transcatheter mitral valve replacement and repair technologies. Its primary product is a transcatheter mitral valve prosthesis designed to be deployed without disrupting the native mitral annulus, while preserving the sub-valvular apparatus. The valve can be placed using a transapical approach, allowing physicians to reposition, remove, or redeploy the valve during the procedure. As of August 2015, Tendyne operates as a subsidiary of Abbott Laboratories.

Aurinia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company headquartered in Victoria, Canada, focused on developing and commercializing therapies for serious diseases with significant unmet medical needs. The company is primarily engaged in the development of voclosporin, an investigational drug aimed at treating lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Aurinia's efforts are concentrated on targeted patient populations in the United States and China, where it seeks to provide innovative solutions for conditions that currently lack effective treatments.

Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, dedicated to developing innovative therapeutics, particularly stabilized cell-permeating alpha-helical peptides, for oncology and other therapeutic areas. The company’s lead product candidate, ALRN-6924, is designed to treat advanced solid tumors and is currently undergoing various clinical trials, including Phase 2a studies for peripheral T-cell lymphoma and advanced solid tumors, as well as Phase 1 trials for acute myeloid leukemia and myelodysplastic syndromes. Aileron Therapeutics also explores next-generation wild type p53 reactivators and has established collaborations with notable institutions such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer to evaluate the effectiveness of ALRN-6924 in combination with other treatments. Founded in 2001 and originally known as Renegade Therapeutics, the company aims to address critical cell functions through its novel approach to modulating protein-protein interactions.

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Irvine, California, specializing in the development of innovative treatments for patients with disorders of the ear, nose, and throat, as well as for those undergoing organ or cellular transplantation and individuals with autoimmune and neurodegenerative diseases. The company’s lead product, OP0201, is a surfactant-based nasal aerosol designed for patients at risk for or suffering from otitis media. Additionally, Eledon has developed a foam-based drug delivery technology, OP0101 and OP0102, aimed at delivering medications to the ear, nose, and sinus cavities. The company also focuses on the CD40L pathway, with its main compound in development, tegoprubart, being an IgG1 anti-CD40L antibody that shows promise for treating autoimmune diseases and supporting organ transplants. Eledon Pharmaceuticals was formerly known as Novus Therapeutics, Inc. before its rebranding in January 2021.

Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, dedicated to developing innovative therapeutics, particularly stabilized cell-permeating alpha-helical peptides, for oncology and other therapeutic areas. The company’s lead product candidate, ALRN-6924, is designed to treat advanced solid tumors and is currently undergoing various clinical trials, including Phase 2a studies for peripheral T-cell lymphoma and advanced solid tumors, as well as Phase 1 trials for acute myeloid leukemia and myelodysplastic syndromes. Aileron Therapeutics also explores next-generation wild type p53 reactivators and has established collaborations with notable institutions such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer to evaluate the effectiveness of ALRN-6924 in combination with other treatments. Founded in 2001 and originally known as Renegade Therapeutics, the company aims to address critical cell functions through its novel approach to modulating protein-protein interactions.

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Irvine, California, specializing in the development of innovative treatments for patients with disorders of the ear, nose, and throat, as well as for those undergoing organ or cellular transplantation and individuals with autoimmune and neurodegenerative diseases. The company’s lead product, OP0201, is a surfactant-based nasal aerosol designed for patients at risk for or suffering from otitis media. Additionally, Eledon has developed a foam-based drug delivery technology, OP0101 and OP0102, aimed at delivering medications to the ear, nose, and sinus cavities. The company also focuses on the CD40L pathway, with its main compound in development, tegoprubart, being an IgG1 anti-CD40L antibody that shows promise for treating autoimmune diseases and supporting organ transplants. Eledon Pharmaceuticals was formerly known as Novus Therapeutics, Inc. before its rebranding in January 2021.

Gloucester Pharmaceuticals is a biopharmaceutical company focused on developing cancer therapeutics, specifically targeting hematological malignancies. Owned by Celgene, the company specializes in acquiring clinical-stage oncology drug candidates and advancing them through regulatory approval and commercialization. Its primary compound, romidepsin, is a late-stage drug candidate classified as a histone deacetylase (HDAC) inhibitor. Romidepsin has demonstrated potential efficacy for various hematological cancers, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and multiple myeloma. Gloucester retains worldwide exclusive rights to romidepsin, which has shown promise as a potent inhibitor of several classes of HDACs, thus positioning the company as a significant player in the oncology therapeutic landscape.

Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, dedicated to developing innovative therapeutics, particularly stabilized cell-permeating alpha-helical peptides, for oncology and other therapeutic areas. The company’s lead product candidate, ALRN-6924, is designed to treat advanced solid tumors and is currently undergoing various clinical trials, including Phase 2a studies for peripheral T-cell lymphoma and advanced solid tumors, as well as Phase 1 trials for acute myeloid leukemia and myelodysplastic syndromes. Aileron Therapeutics also explores next-generation wild type p53 reactivators and has established collaborations with notable institutions such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer to evaluate the effectiveness of ALRN-6924 in combination with other treatments. Founded in 2001 and originally known as Renegade Therapeutics, the company aims to address critical cell functions through its novel approach to modulating protein-protein interactions.

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Irvine, California, specializing in the development of innovative treatments for patients with disorders of the ear, nose, and throat, as well as for those undergoing organ or cellular transplantation and individuals with autoimmune and neurodegenerative diseases. The company’s lead product, OP0201, is a surfactant-based nasal aerosol designed for patients at risk for or suffering from otitis media. Additionally, Eledon has developed a foam-based drug delivery technology, OP0101 and OP0102, aimed at delivering medications to the ear, nose, and sinus cavities. The company also focuses on the CD40L pathway, with its main compound in development, tegoprubart, being an IgG1 anti-CD40L antibody that shows promise for treating autoimmune diseases and supporting organ transplants. Eledon Pharmaceuticals was formerly known as Novus Therapeutics, Inc. before its rebranding in January 2021.

Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, dedicated to developing innovative therapeutics, particularly stabilized cell-permeating alpha-helical peptides, for oncology and other therapeutic areas. The company’s lead product candidate, ALRN-6924, is designed to treat advanced solid tumors and is currently undergoing various clinical trials, including Phase 2a studies for peripheral T-cell lymphoma and advanced solid tumors, as well as Phase 1 trials for acute myeloid leukemia and myelodysplastic syndromes. Aileron Therapeutics also explores next-generation wild type p53 reactivators and has established collaborations with notable institutions such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer to evaluate the effectiveness of ALRN-6924 in combination with other treatments. Founded in 2001 and originally known as Renegade Therapeutics, the company aims to address critical cell functions through its novel approach to modulating protein-protein interactions.

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Irvine, California, specializing in the development of innovative treatments for patients with disorders of the ear, nose, and throat, as well as for those undergoing organ or cellular transplantation and individuals with autoimmune and neurodegenerative diseases. The company’s lead product, OP0201, is a surfactant-based nasal aerosol designed for patients at risk for or suffering from otitis media. Additionally, Eledon has developed a foam-based drug delivery technology, OP0101 and OP0102, aimed at delivering medications to the ear, nose, and sinus cavities. The company also focuses on the CD40L pathway, with its main compound in development, tegoprubart, being an IgG1 anti-CD40L antibody that shows promise for treating autoimmune diseases and supporting organ transplants. Eledon Pharmaceuticals was formerly known as Novus Therapeutics, Inc. before its rebranding in January 2021.

Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, dedicated to developing innovative therapeutics, particularly stabilized cell-permeating alpha-helical peptides, for oncology and other therapeutic areas. The company’s lead product candidate, ALRN-6924, is designed to treat advanced solid tumors and is currently undergoing various clinical trials, including Phase 2a studies for peripheral T-cell lymphoma and advanced solid tumors, as well as Phase 1 trials for acute myeloid leukemia and myelodysplastic syndromes. Aileron Therapeutics also explores next-generation wild type p53 reactivators and has established collaborations with notable institutions such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer to evaluate the effectiveness of ALRN-6924 in combination with other treatments. Founded in 2001 and originally known as Renegade Therapeutics, the company aims to address critical cell functions through its novel approach to modulating protein-protein interactions.

Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, dedicated to developing innovative therapeutics, particularly stabilized cell-permeating alpha-helical peptides, for oncology and other therapeutic areas. The company’s lead product candidate, ALRN-6924, is designed to treat advanced solid tumors and is currently undergoing various clinical trials, including Phase 2a studies for peripheral T-cell lymphoma and advanced solid tumors, as well as Phase 1 trials for acute myeloid leukemia and myelodysplastic syndromes. Aileron Therapeutics also explores next-generation wild type p53 reactivators and has established collaborations with notable institutions such as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and Pfizer to evaluate the effectiveness of ALRN-6924 in combination with other treatments. Founded in 2001 and originally known as Renegade Therapeutics, the company aims to address critical cell functions through its novel approach to modulating protein-protein interactions.

Gloucester Pharmaceuticals is a biopharmaceutical company focused on developing cancer therapeutics, specifically targeting hematological malignancies. Owned by Celgene, the company specializes in acquiring clinical-stage oncology drug candidates and advancing them through regulatory approval and commercialization. Its primary compound, romidepsin, is a late-stage drug candidate classified as a histone deacetylase (HDAC) inhibitor. Romidepsin has demonstrated potential efficacy for various hematological cancers, including cutaneous T-cell lymphoma, peripheral T-cell lymphoma, and multiple myeloma. Gloucester retains worldwide exclusive rights to romidepsin, which has shown promise as a potent inhibitor of several classes of HDACs, thus positioning the company as a significant player in the oncology therapeutic landscape.

Cyrano Sciences, is focused on providing chemical and biological sensors and software solutions.